• Consensus Rating: Buy
  • Consensus Price Target: $47.50
  • Forecasted Upside: 0.42%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.36 (-0.76%)

This chart shows the closing price for BHVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biohaven Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BHVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHVN

Analyst Price Target is $47.50
▲ +0.42% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Biohaven in the last 3 months. The average price target is $47.50, with a high forecast of $62.00 and a low forecast of $28.00. The average price target represents a 0.42% upside from the last price of $47.30.

This chart shows the closing price for BHVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Biohaven. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$32.00 ➝ $56.00Low
2/16/2024Royal Bank of CanadaInitiated CoverageOutperform$62.00Low
2/6/2024UBS GroupInitiated CoverageBuy$59.00Low
12/22/2023HC WainwrightInitiated CoverageBuy$50.00Low
12/8/2023Robert W. BairdInitiated CoverageOutperform$58.00Low
11/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$26.00 ➝ $32.00Low
11/15/2023Piper SandlerBoost TargetOverweight ➝ Overweight$29.00 ➝ $36.00Low
8/16/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$27.00 ➝ $24.00Low
6/5/2023BTIG ResearchBoost Target$24.00 ➝ $28.00Low
4/4/2023Cantor FitzgeraldBoost TargetOverweight$27.00 ➝ $31.00Low
1/24/2023SVB LeerinkReiterated RatingOutperform$24.00Low
1/24/2023SVB SecuritiesInitiated CoverageOutperform$24.00Low
1/4/2023JPMorgan Chase & Co.Initiated CoverageOverweight$23.00Low
12/2/2022BTIG ResearchInitiated CoverageBuy$24.00Low
11/7/2022CowenSet Target$25.00Low
11/7/2022CowenLower Target$25.00Low
10/26/2022Cantor FitzgeraldUpgradeNeutral ➝ Overweight$158.00 ➝ $27.00Low
10/26/2022Piper SandlerLower TargetOverweight$23.00 ➝ $21.00Low
10/12/2022Piper SandlerInitiated CoverageOverweight$23.00Low
8/18/2022Piper SandlerDowngradeOverweight ➝ Neutral$149.00Low
8/8/2022WedbushDowngradeOutperform ➝ Neutral$148.50Low
5/24/2022Piper SandlerLower TargetNA$156.00 ➝ $149.00Low
5/11/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
5/11/2022HC WainwrightDowngradeBuy ➝ NeutralLow
5/11/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$150.00Low
4/6/2022Morgan StanleyLower TargetEqual Weight$148.00 ➝ $146.00High
3/3/2022MizuhoBoost TargetBuy$144.00 ➝ $154.00Low
1/7/2022HC WainwrightReiterated RatingBuy$160.00High
1/7/2022Morgan StanleyBoost TargetEqual Weight$145.00 ➝ $148.00Medium
1/4/2022UBS GroupBoost Target$150.00 ➝ $160.00High
12/7/2021HC WainwrightReiterated RatingBuy$160.00Low
11/18/2021MizuhoBoost TargetPositive ➝ Buy$135.00 ➝ $144.00Medium
11/10/2021Cantor FitzgeraldBoost TargetOverweight$165.00 ➝ $177.00Medium
11/10/2021MizuhoLower TargetBuy$137.00 ➝ $135.00Medium
10/19/2021Morgan StanleyBoost TargetEqual Weight$107.00 ➝ $145.00Low
10/7/2021SVB LeerinkReiterated RatingBuyLow
10/6/2021HC WainwrightReiterated RatingBuy$135.00 ➝ $160.00Low
10/6/2021The Goldman Sachs GroupBoost TargetBuy$151.00 ➝ $170.00Low
10/5/2021MizuhoReiterated RatingBuy$137.00Low
10/5/2021Piper SandlerBoost TargetOverweight$140.00 ➝ $156.00Medium
9/13/2021Cantor FitzgeraldBoost TargetOverweight$151.00 ➝ $165.00High
8/10/2021UBS GroupDowngradeBuy ➝ Neutral$108.00 ➝ $109.00High
7/16/2021Morgan StanleyBoost TargetEqual Weight$69.00 ➝ $107.00High
7/12/2021MizuhoBoost TargetBuy$92.00 ➝ $134.00Low
7/8/2021HC WainwrightBoost TargetBuy$111.00 ➝ $135.00High
7/7/2021CowenBoost TargetOutperform$90.00 ➝ $130.00High
6/1/2021Cantor FitzgeraldBoost TargetOverweight$125.00 ➝ $140.00High
5/28/2021MizuhoBoost TargetBuy$90.00 ➝ $92.00Low
5/18/2021Morgan StanleyLower TargetEqual Weight$76.00 ➝ $69.00High
5/12/2021SVB LeerinkLower TargetOutperform$115.00 ➝ $105.00Medium
5/11/2021MizuhoLower TargetBuy$98.00 ➝ $90.00Medium
5/3/2021MizuhoLower TargetBuy$103.00 ➝ $98.00N/A
4/26/2021MizuhoLower TargetBuy$103.00 ➝ $98.00Low
4/19/2021Morgan StanleyBoost TargetEqual Weight$73.00 ➝ $76.00Medium
3/11/2021UBS GroupInitiated CoverageBuy$108.00High
3/2/2021MizuhoBoost TargetBuy$93.00 ➝ $103.00High
3/1/2021Piper SandlerBoost TargetOverweight$90.00 ➝ $110.00Low
2/5/2021William BlairReiterated RatingBuyMedium
1/19/2021MizuhoLower Target$100.00 ➝ $93.00High
1/19/2021HC WainwrightLower TargetBuy$121.00 ➝ $111.00High
12/29/2020Cantor FitzgeraldBoost TargetOverweight$109.00 ➝ $115.00N/A
12/16/2020Morgan StanleyBoost TargetEqual Weight$63.00 ➝ $73.00Medium
12/15/2020HC WainwrightInitiated CoverageBuy$121.00Medium
12/7/2020SVB LeerinkBoost TargetOutperform$85.00 ➝ $120.00Medium
11/13/2020MizuhoBoost TargetBuy$82.00 ➝ $100.00Low
10/13/2020WedbushBoost TargetOutperform$96.00 ➝ $99.00Low
10/13/2020Morgan StanleyBoost TargetEqual Weight$57.00 ➝ $63.00Low
8/24/2020Morgan StanleyLower TargetEqual Weight$60.00 ➝ $57.00High
8/10/2020William BlairReiterated RatingBuyHigh
7/15/2020Morgan StanleyBoost TargetEqual Weight$50.00 ➝ $60.00Low
6/26/2020MizuhoInitiated CoverageBuy$85.00Low
6/23/2020Cantor FitzgeraldBoost TargetOverweight$82.00 ➝ $109.00Low
6/18/2020WedbushBoost TargetOutperform$74.00 ➝ $94.00Low
6/15/2020CowenBoost TargetOutperform$60.00 ➝ $80.00High
6/9/2020MizuhoReiterated RatingBuy$53.00 ➝ $85.00High
5/20/2020MizuhoReiterated RatingBuy$53.00High
5/11/2020Cantor FitzgeraldBoost TargetOverweight$75.00 ➝ $82.00Low
5/11/2020Morgan StanleyBoost TargetEqual Weight$46.00 ➝ $50.00High
5/8/2020OppenheimerReiterated RatingHold$41.00Low
4/17/2020CowenInitiated CoverageOutperform$45.00High
4/15/2020Morgan StanleyLower TargetEqual Weight$49.00 ➝ $46.00Medium
3/31/2020OppenheimerLower TargetMarket Perform$48.00 ➝ $37.00Low
3/13/2020WedbushBoost TargetOutperform$73.00 ➝ $78.00High
2/23/2020MizuhoReiterated RatingBuy$58.00High
2/10/2020The Goldman Sachs GroupLower TargetBuy$89.00 ➝ $76.00Medium
2/10/2020OppenheimerDowngradeOutperform ➝ Market Perform$67.00 ➝ $51.00High
2/5/2020MizuhoInitiated CoverageBuy$62.00Low
1/29/2020WedbushReiterated RatingBuy$75.00High
12/23/2019Piper Sandler CompaniesReiterated RatingBuy$100.00Medium
12/17/2019Piper Sandler CompaniesReiterated RatingBuy$100.00Medium
12/12/2019WedbushInitiated CoverageOutperform$75.00Low
12/10/2019William BlairReiterated RatingBuyLow
12/6/2019SVB LeerinkBoost TargetPositive ➝ Outperform$62.00 ➝ $64.00Medium
11/27/2019WedbushInitiated CoverageOutperform$75.00N/A
11/21/2019WedbushInitiated CoverageOutperform$75.00High
10/28/2019Cantor FitzgeraldBoost TargetOverweight$87.00 ➝ $92.00High
10/9/2019OppenheimerSet TargetBuy$67.00N/A
9/17/2019William BlairReiterated RatingBuyLow
9/4/2019Cantor FitzgeraldSet TargetBuy$87.00Low
9/4/2019The Goldman Sachs GroupSet TargetBuy$89.00Low
8/9/2019Morgan StanleySet TargetHold$50.00High
7/22/2019Morgan StanleyLower TargetEqual Weight$55.00 ➝ $51.00High
7/15/2019Morgan StanleySet TargetHold$55.00Low
6/19/2019OppenheimerSet TargetBuy$68.00Medium
5/31/2019BarclaysReiterated RatingHold$55.00Low
5/14/2019Morgan StanleyBoost TargetEqual Weight$55.00 ➝ $57.00High
5/8/2019Needham & Company LLCBoost TargetBuy$70.00High
5/8/2019Piper Sandler CompaniesBoost TargetOverweight$75.00 ➝ $100.00High
5/6/2019The Goldman Sachs GroupInitiated CoverageBuy$92.00 ➝ $92.00High
4/23/2019SVB LeerinkBoost TargetOutperform$50.00 ➝ $67.00Medium
4/15/2019OppenheimerBoost TargetOutperform ➝ Outperform$54.00 ➝ $70.00Low
4/9/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$49.13Low
3/19/2019BarclaysReiterated RatingHold$52.00Medium
3/19/2019OppenheimerReiterated RatingBuyLow
3/18/2019Piper Sandler CompaniesSet TargetBuy$75.00Low
3/6/2019Cantor FitzgeraldBoost TargetOverweight$82.00High
3/4/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$48.00 ➝ $56.00Medium
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 7 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 11 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 11 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Biohaven logo
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Read More

Today's Range

Now: $47.30
Low: $46.26
High: $48.04

50 Day Range

MA: $45.16
Low: $37.92
High: $49.50

52 Week Range

Now: $47.30
Low: $12.35
High: $50.68


824,295 shs

Average Volume

927,516 shs

Market Capitalization

$3.79 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Biohaven?

The following Wall Street sell-side analysts have issued stock ratings on Biohaven in the last twelve months: BTIG Research, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, Royal Bank of Canada, and UBS Group AG.
View the latest analyst ratings for BHVN.

What is the current price target for Biohaven?

8 Wall Street analysts have set twelve-month price targets for Biohaven in the last year. Their average twelve-month price target is $47.50, suggesting a possible upside of 0.4%. Royal Bank of Canada has the highest price target set, predicting BHVN will reach $62.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $28.00 for Biohaven in the next year.
View the latest price targets for BHVN.

What is the current consensus analyst rating for Biohaven?

Biohaven currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BHVN will outperform the market and that investors should add to their positions of Biohaven.
View the latest ratings for BHVN.

What other companies compete with Biohaven?

How do I contact Biohaven's investor relations team?

Biohaven's physical mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company's listed phone number is 203-404-0410 and its investor relations email address is [email protected]. The official website for Biohaven is www.biohavenpharma.com. Learn More about contacing Biohaven investor relations.